智通财经网·2025-11-12 02:14Core Viewpoint - JD Health's stock has risen over 4%, driven by strong sales growth in pharmaceuticals and health products, with a projected revenue increase for Q3 [1] Group 1: Financial Performance - JD Health's pharmaceutical sales grew over 30% year-on-year in Q3, supported by prescription drugs and chronic disease medications [1] - Health products maintained a year-on-year growth of over 20%, contributing to an expected total revenue increase of 25% to 16.6 billion RMB for Q3 [1] - Adjusted EBIT is projected to rise over 40% year-on-year to 1.2 billion RMB [1] Group 2: Future Outlook - The company plans to open 200 new stores in the second half of the year, having opened only 50 in Q3 [1] - UBS anticipates that the strong revenue growth momentum from the first half of the year will continue into Q3, with sustained growth across different product categories [1] - The expected revenue growth for the second half of the year is 20%, indicating a 16% increase in Q4 [1]